News

Bladder Cancer Awareness Month: a breakthrough for early diagnosis

By nonacus-developer / April 17, 2024 /

Written by Victoria Simms May 2023. Reviewed by Celina Whalley April 2024 APRIL 17, 2024 | COMPANY | NEWS May marks Bladder Cancer Awareness Month, four weeks dedicated to raising awareness of this disease, its symptoms, and the current realities for those impacted by bladder cancer both directly and indirectly. As we continue to implement…

Read More

Read all about it in The Telegraph – the potential of GALEAS Bladder in the early diagnosis of bladder cancer

By Celina Whalley / April 12, 2024 / Comments Off on Read all about it in The Telegraph – the potential of GALEAS Bladder in the early diagnosis of bladder cancer

April 12, 2024 | COMPANY | NEWS Bladder Cancer Awareness month is quickly approaching and Nonacus is delighted to share that The Daily Telegraph has published an article about recognising the symptoms of bladder cancer, and the importance of early diagnosis of bladder cancer featuring GALEAS Bladder. This piece features insightful interviews from key opinion…

Read More

Nonacus launches test for comprehensive genomic profiling, integrated with bioinformatics and analysis software

By Victoria Simms / April 2, 2024 /

April 2, 2024 | COMPANY | NEWS Genetic testing company, Nonacus, has launched GALEASTM Tumor, a next generation sequencing (NGS) test that provides comprehensive genomic profiling of tumors, allowing clinicians to accurately diagnose cancers and tailor treatments. Comprehensive genomic profiling (CGP) is a well-established technique used to analyse the genomic profile of a tumor, allowing…

Read More

New genetic test to speed up and streamline diagnosis of inherited cancers

By Victoria Simms / January 24, 2024 /

January 24, 2024 | COMPANY | NEWS Nonacus has launched its latest next generation sequencing (NGS) test in the GALEAS product range – the GALEAS HereditaryPlus panel – which provides laboratories and clinicians with a comprehensive and streamlined way to diagnose patients with cancer that is caused by inherited genetic mutations. Eliminating the need for MLPA in hereditary…

Read More

Grand Opening of Advanced Genomics APAC Taiwan Headquarters

By Victoria Simms / October 5, 2023 / Comments Off on Grand Opening of Advanced Genomics APAC Taiwan Headquarters

October 5, 2023 | COMPANY | NEWS Signal of Strong Commitment to Innovative Medical Services Focused on Early Cancer Detection and Companion Testing Nonacus CEO Chris Sale and Advanced Genomics APAC Co. Ltd. Managing Director Andy Chang Advanced Genomics APAC Co. Ltd. proudly announced today the grand opening of its Taiwan headquarters, marking a significant…

Read More

Introducing our new logo and brand identity: reflecting Nonacus’ clinical vision for advanced liquid biopsy testing

By nonacus-developer / May 26, 2023 /

MAY 29, 2023 | COMPANY | NEWS Introducing our new logo and brand identity: reflecting Nonacus’ clinical vision for advanced liquid biopsy testing As we continue to drive innovation in the field, we have honed our focus towards decentralised and cost-effective cancer genomics through our state-of-the-art liquid biopsy testing platform. This rebranding effort signifies our…

Read More

Liquid biopsy company Nonacus unveils new Birmingham headquarters with distinguished presence of Angela Douglas MBE

By nonacus-developer / May 17, 2023 /

MAY 17, 2023 | COMPANY | NEWS Liquid biopsy company Nonacus and genomic testing laboratory Informed Genomics officially opened their new Birmingham Headquarters yesterday with a ribbon-cutting ceremony led by Angela Douglas MBE, Deputy Chief Scientific Officer for NHS England. Nonacus, a leading liquid biopsy company, and genomic testing laboratory Informed Genomics, marked a significant…

Read More

Nonacus launches GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer

By nonacus-developer / March 29, 2023 /

MARCH 29, 2023 | COMPANY | NEWS The urine-based molecular test can quickly and accurately detect bladder cancer and streamline diagnosis, thereby reducing the need for invasive cystoscopies. Nonacus launched GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer at the European Association of Urology (EAU) Annual Meeting in Milan on 10-13th March 2023.…

Read More

Nonacus invests in early bowel cancer detection start-up CanSense

By nonacus-developer / March 14, 2023 /

MARCH 9, 2023 | COMPANY | NEWS Nonacus is delighted to announce its investment in CanSense: a Swansea-based start-up company focused on the early detection of bowel cancer through a simple blood test. CanSense’s test, which combines laser spectroscopy with artificial intelligence, is faster, less expensive and less invasive than a colonoscopy procedure and more…

Read More

Nonacus ranked third fastest growing technology company in the UK in the Deloitte Technology Fast 50

By nonacus-developer / November 24, 2022 /

November 24, 2022 | COMPANY | NEWS Nonacus has been ranked within the top three fastest growing tech companies in the U.K, and first in healthcare, at the prestigious 2022 Deloitte Tech Fast 50 awards. The Deloitte UK Technology Fast 50 is a ranking of the 50 fastest-growing technology companies in the UK. The rankings…

Read More